Biosyngen, an immuno-oncology startup with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, has announced the official opening of its latest Good Manufacturing Practice (GMP) facility in Singapore.

The facility will support cell manufacturing for immunotherapies in Singapore and across the world, and create more than 200 jobs for the cell and gene therapy (CGT) industry in the next three to five years.

The new facility is the first and largest privately-owned, fully automatic, enclosed and integrated GMP cell manufacturing facility and Research & Development base in Singapore to date.

The company has also signed an agreements to set up a China-Singapore Technology Innovation and Translational Medicine Centre for Tumour Prevention and Treatment as part of the Singapore-Guangdong Collaboration Council (SGCC).

Biosyngen is also working closely with stakeholders in the Singapore healthcare ecosystem, collaborating with the National Cancer Centre Singapore (NCCS) to conduct a basket of clinical trials for various cancer indications and biomarker discovery to enhance patient selection and effectiveness. 

Image caption- [From Left to Right] Dr Han Deping, Chief Medical Officer, Biosyngen; Dr Cheong Wei Yang, Deputy Secretary (Technology), Ministry of Health; Ms Joan Zhang, Chairman, Biosyngen; Mr Alvin Tan, Minister of State for the Ministry of Trade & Industry; Ms Lily Peng Yuemei, Deputy Party Secretary, Director, Knowledge City (Guangzhou) Investment Group and Dr Michelle Chen, Chief Operating Officer, Biosyngen